Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28754410 | 0.86 | EGLN2 (0.37) | PKMEGLN2SCN9ASYKCTSA | |
| SCHEMBL29170111 | 0.85 | CXCR2 (0.35) | SCN9AGSK3BHSD11B1 | |
| SCHEMBL28786609 | 0.84 | L3MBTL1 (0.39) | PKMEGLN2SCN9ACTSAFNTA | |
| SCHEMBL29170084 | 0.84 | TTR (0.33) | SCN9AGSK3BHSD11B1 | |
| SCHEMBL29170133 | 0.80 | SCN9A (0.34) | SCN9AHSD11B1 | |
| SCHEMBL29160117 | 0.80 | S1PR3 (0.33) | PKMEGLN2 | |
| SCHEMBL29170139 | 0.80 | SCN9A (0.41) | SCN9A | |
| SCHEMBL29170159 | 0.79 | SCN9A (0.37) | SCN9AGSK3B | |
| SCHEMBL29170154 | 0.78 | SCN9A (0.31) | SCN9AGSK3BHSD11B1 | |
| SCHEMBL29160234 | 0.78 | EGLN2 (0.35) | PKMEGLN2CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-113853371-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117279905-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114008033-A | Glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| CN-113853371-A | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | PKM 1104/4885EGLN2 3345/4885SCN9A 607/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | PKM 1223/4885EGLN2 1342/4885SCN9A 1422/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | PKM 1012/4885EGLN2 1420/4885SCN9A 2808/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | PKM 1223/4885EGLN2 1342/4885SCN9A 1422/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | PKM 1125/4885EGLN2 1031/4885SCN9A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.